Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.

@article{Spranger2017TumorResidingBD,
  title={Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.},
  author={Stefani Spranger and Daisy Dai and Brendan L Horton and Thomas F Gajewski},
  journal={Cancer cell},
  year={2017},
  volume={31 5},
  pages={711-723.e4}
}
Effector T cells have the capability of recognizing and killing cancer cells. However, whether tumors can become immune resistant through exclusion of effector T cells from the tumor microenvironment is not known. By using a tumor model resembling non-T cell-inflamed human tumors, we assessed whether adoptive T cell transfer might overcome failed spontaneous priming. Flow cytometric assays combined with intra-vital imaging indicated failed trafficking of effector T cells into tumors… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2018
View 4 Excerpts
Highly Influenced

Activation of viral defense signaling in cancer

Therapeutic advances in medical oncology • 2018

References

Publications referenced by this paper.
Showing 1-10 of 48 references

Similar Papers

Loading similar papers…